Neuroimmune lipidome dysregulation in major depressive disorder: A meta-analysis of peripheral endocannabinoid and N-acylethanolamine signaling.
Muhammad Yaseen, Wei-Jen Chen, Jane Pei-Chen Chang et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and random-effects meta-analysis examined peripheral endocannabinoids and N-acylethanolamines in case-control and cross-sectional studies of people with major depressive disorder (MDD) versus healthy controls. Across nine studies (514 individuals with MDD and 417 controls), circulating anandamide (AEA) and palmitoylethanolamide (PEA) were higher in MDD: AEA SMD = 0.32, 95 % CI: 0.10 - 0.54, p < 0.01; PEA SMD = 0.35, 95 % CI: 0.04 - 0.65, p = 0.03. No significant differences were found for 2-AG or OEA.
Key findings
- AEA was higher in MDD than in controls (SMD = 0.32, 95 % CI: 0.10 - 0.54, p < 0.01).
- PEA was higher in MDD than in controls (SMD = 0.35, 95 % CI: 0.04 - 0.65, p = 0.03).
- No significant group differences were observed for 2-AG or OEA.
- AEA elevations were more pronounced among medicated patients and those with psychiatric comorbidities.
Why it matters
The findings suggest that peripheral lipid mediators related to endocannabinoid and N-acylethanolamine signaling are not uniformly altered in MDD. The selective elevations in AEA and PEA may help guide research into biological heterogeneity and candidate peripheral biomarkers, while the subgroup patterns highlight the need to account for medication and psychiatric comorbidity when interpreting these measures.
What to keep in mind
The evidence came from nine case-control and cross-sectional studies, so it cannot establish whether lipid changes precede or result from MDD. The authors note that longitudinal and mechanistic studies are needed to clarify treatment and comorbidity effects.